Evidence map›Paper›PMID 29948237›Full record

ArticleMagma (New York, N.Y.)2019

Improvement of

Bu S Park, Ge Ma, William T Koch, Sunder S Rajan, Manuel Mastromanolis, Johnny Lam, Kyung Sung, Brent McCright

Abstract read
PubMed Publisher
In one paragraph

Article in Magma (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bu S ParkDivision of Cellular and Gene Therapies (DCGT)/OTAT/CBER, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA. Bu.Park@fda.hhs.gov.ORCID http://orcid.org/0000-0003-0196-6598
Ge MaDivision of Cellular and Gene Therapies (DCGT)/OTAT/CBER, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA.
William T KochDivision of Cellular and Gene Therapies (DCGT)/OTAT/CBER, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA.
Sunder S RajanDivision of Biomedical Physics (DBP)/OSEL/CDRH, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA.
Manuel MastromanolisDivision of Cellular and Gene Therapies (DCGT)/OTAT/CBER, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA.
Johnny LamDivision of Cellular and Gene Therapies (DCGT)/OTAT/CBER, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA.
Kyung SungDivision of Cellular and Gene Therapies (DCGT)/OTAT/CBER, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA.
Brent McCrightDivision of Cellular and Gene Therapies (DCGT)/OTAT/CBER, Food and Drug Administration, Silver Spring, MD, 20993-0002, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveImprove MATERIALS AND

methodsFollowing Faraday's induction law, the sign of induced B

resultsThe numerical simulation results of rotating transmit B

conclusionThe secondary resonator tuned to enhance the induced B

Indexed as

Fluorine-19 Magnetic Resonance ImagingMagnetic FieldsStem Cell TransplantationAnimalsCell TrackingEquipment DesignFluorineFluorocarbonsMiceModels, TheoreticalPhantoms, ImagingRadio WavesSignal-To-Noise RatioFluorineFluorocarbons19F MRComputational modelingFluorine MRPerfluorocarbonPolyethylene glycolResonator

Identifiers

PMID29948237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.